Cargando…
Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism
PARK2 (parkin) mutations cause early-onset Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that participates in several cellular functions, including mitochondrial homeostasis. However, the specific metabolomic changes caused by parkin depletion remain unknown. Here, we used isogenic...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190670/ https://www.ncbi.nlm.nih.gov/pubmed/34048689 http://dx.doi.org/10.1016/j.stemcr.2021.04.022 |
_version_ | 1783705732987748352 |
---|---|
author | Okarmus, Justyna Havelund, Jesper F. Ryding, Matias Schmidt, Sissel I. Bogetofte, Helle Heon-Roberts, Rachel Wade-Martins, Richard Cowley, Sally A. Ryan, Brent J. Færgeman, Nils J. Hyttel, Poul Meyer, Morten |
author_facet | Okarmus, Justyna Havelund, Jesper F. Ryding, Matias Schmidt, Sissel I. Bogetofte, Helle Heon-Roberts, Rachel Wade-Martins, Richard Cowley, Sally A. Ryan, Brent J. Færgeman, Nils J. Hyttel, Poul Meyer, Morten |
author_sort | Okarmus, Justyna |
collection | PubMed |
description | PARK2 (parkin) mutations cause early-onset Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that participates in several cellular functions, including mitochondrial homeostasis. However, the specific metabolomic changes caused by parkin depletion remain unknown. Here, we used isogenic human induced pluripotent stem cells (iPSCs) with and without PARK2 knockout (KO) to investigate the effect of parkin loss of function by comparative metabolomics supplemented with ultrastructural and functional analyses. PARK2 KO neurons displayed increased tricarboxylic acid (TCA) cycle activity, perturbed mitochondrial ultrastructure, ATP depletion, and dysregulation of glycolysis and carnitine metabolism. These perturbations were combined with increased oxidative stress and a decreased anti-oxidative response. Key findings for PARK2 KO cells were confirmed using patient-specific iPSC-derived neurons. Overall, our data describe a unique metabolomic profile associated with parkin dysfunction and show that combining metabolomics with an iPSC-derived dopaminergic neuronal model of PD is a valuable approach to obtain novel insight into the disease pathogenesis. |
format | Online Article Text |
id | pubmed-8190670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81906702021-06-17 Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism Okarmus, Justyna Havelund, Jesper F. Ryding, Matias Schmidt, Sissel I. Bogetofte, Helle Heon-Roberts, Rachel Wade-Martins, Richard Cowley, Sally A. Ryan, Brent J. Færgeman, Nils J. Hyttel, Poul Meyer, Morten Stem Cell Reports Article PARK2 (parkin) mutations cause early-onset Parkinson's disease (PD). Parkin is an ubiquitin E3 ligase that participates in several cellular functions, including mitochondrial homeostasis. However, the specific metabolomic changes caused by parkin depletion remain unknown. Here, we used isogenic human induced pluripotent stem cells (iPSCs) with and without PARK2 knockout (KO) to investigate the effect of parkin loss of function by comparative metabolomics supplemented with ultrastructural and functional analyses. PARK2 KO neurons displayed increased tricarboxylic acid (TCA) cycle activity, perturbed mitochondrial ultrastructure, ATP depletion, and dysregulation of glycolysis and carnitine metabolism. These perturbations were combined with increased oxidative stress and a decreased anti-oxidative response. Key findings for PARK2 KO cells were confirmed using patient-specific iPSC-derived neurons. Overall, our data describe a unique metabolomic profile associated with parkin dysfunction and show that combining metabolomics with an iPSC-derived dopaminergic neuronal model of PD is a valuable approach to obtain novel insight into the disease pathogenesis. Elsevier 2021-05-27 /pmc/articles/PMC8190670/ /pubmed/34048689 http://dx.doi.org/10.1016/j.stemcr.2021.04.022 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Okarmus, Justyna Havelund, Jesper F. Ryding, Matias Schmidt, Sissel I. Bogetofte, Helle Heon-Roberts, Rachel Wade-Martins, Richard Cowley, Sally A. Ryan, Brent J. Færgeman, Nils J. Hyttel, Poul Meyer, Morten Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism |
title | Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism |
title_full | Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism |
title_fullStr | Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism |
title_full_unstemmed | Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism |
title_short | Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism |
title_sort | identification of bioactive metabolites in human ipsc-derived dopaminergic neurons with park2 mutation: altered mitochondrial and energy metabolism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190670/ https://www.ncbi.nlm.nih.gov/pubmed/34048689 http://dx.doi.org/10.1016/j.stemcr.2021.04.022 |
work_keys_str_mv | AT okarmusjustyna identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT havelundjesperf identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT rydingmatias identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT schmidtsisseli identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT bogetoftehelle identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT heonrobertsrachel identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT wademartinsrichard identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT cowleysallya identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT ryanbrentj identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT færgemannilsj identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT hyttelpoul identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism AT meyermorten identificationofbioactivemetabolitesinhumanipscderiveddopaminergicneuronswithpark2mutationalteredmitochondrialandenergymetabolism |